Liver Cancer Therapeutics Market Analyzed & Forecast in New In-Demand GBI Research Report Available at MarketPublishers.com

14 Jan 2013 • by Natalie Aster

LONDON – The global market for liver cancer therapeutics was estimated slightly above USD 380 million in 2009, up by approximately over forth from 2001. Such considerable growth was attributed to the approval of a new cutting-edge drug (Nexavar) in 2007. Since then, the market has continued to register regular growth. It is expected to reach a USD 1.18 billion mark in 2017. At present, the US, France, the UK, Japan, Spain, Germany and Italy are amid the top-class players of the industry. In 2011, the liver cancer therapeutics market in these countries was over USD 374 million, an increase by 22 percent if compared to 2004. It is likely to start generating around USD 644 million in revenues in late 2017.

Upcoming launches of new drugs such as ThermoDox and PrevOnco in 2014-2015, rising liver treatment costs together with growth in the patient volume are set to remain the main contributors to the market growth.

New market research report “Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail” developed by GBI Research is a unique source of the valuable data on the liver cancer therapeutics market with a special focus on US and Japanese markets as well as top five European markets (the UK, Germany, France, Italy and Spain). The report offers an all-inclusive overview of the most prominent products available on the market. It discusses therapeutics R&D pipeline and factors fuelling and restraining the market growth. The research study also includes an analysis of competitive landscape and the world pipeline for all the liver cancer molecules. Future market outlook through 2018 can be found in the report too.

Report Details:

Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail
Published: December, 2012
Pages: 72
Price: US$ 3,500.00

More In-Demand Market Research Reports by GBI Research Include:

More insightful market research reports by the publisher are available at GBI Research page.

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com